```html

Fibrinogen Deficiency – Comprehensive Medical Guide

Overview

Fibrinogen deficiency is a rare inherited or acquired disorder in which the blood lacks sufficient functional fibrinogen, a protein essential for clot formation. Fibrinogen (also called factor I) is produced by the liver and converted by thrombin into fibrin, the mesh that stabilizes a blood clot. When fibrinogen levels are too low, bleeding can occur from even minor injuries, and in severe cases, spontaneous internal bleeding may develop.

The condition is classified into three main sub‑types:

• Congenital afibrinogenemia – < 10 mg/dL fibrinogen (essentially absent).
• Congenital hypofibrinogenemia – 10–150 mg/dL (partial deficiency).
• Acquired deficiency – due to liver disease, disseminated intravascular coagulation (DIC), massive transfusion, or certain medications.

Who it affects: The inherited forms are autosomal recessive, so they occur most often in families with consanguineous marriages or in populations where a specific mutation is common (e.g., certain Middle‑Eastern and Mediterranean groups). The overall prevalence of congenital afibrinogenemia is estimated at 1–2 per million people worldwide, while hypofibrinogenemia is approximately 1 per 100,000‑200,000 people.<sup>[1][2]</sup> Acquired deficiency is far more common and mirrors the epidemiology of its underlying causes (e.g., liver cirrhosis affects up to 10 % of adults in the United States).<sup>[3]</sup>

Symptoms

Bleeding tendencies vary with the severity of the deficiency. Below is a complete list of potential signs and symptoms, along with a brief description of each.

Typical bleeding manifestations

• Nosebleeds (epistaxis) – frequent, often prolonged.
• Gum bleeding – difficulty achieving hemostasis after brushing or dental work.
• Easy bruising (purpura) – large, dark bruises after minor trauma.
• Prolonged bleeding after cuts, scrapes or surgery – clot takes longer to form.
• Hematuria – blood in the urine, usually from mucosal bleeding.
• Menorrhagia – heavy menstrual periods, common in women with hypofibrinogenemia.
• GI bleeding – melena or hematochezia, especially in severe deficiency.
• Intracranial hemorrhage – rare but life‑ threatening; can present with headache, vomiting, seizures, or loss of consciousness.
• Hemarthrosis – bleeding into joints, leading to swelling and pain (more typical in severe forms).

Symptoms specific to acquired deficiency

• Signs of underlying liver disease (jaundice, spider angiomas).
• Evidence of DIC (multiple organ dysfunction, widespread petechiae).
• Post‑operative bleeding despite normal platelet counts.

Causes and Risk Factors

Fibrinogen deficiency can be inherited (congenital) or develop later in life (acquired).

Congenital (Inherited) Causes

• Mutations in the FGA, FGB, or FGG genes – these encode the three polypeptide chains (Aα, Bβ, γ) that combine to form fibrinogen. Over 150 pathogenic variants have been described.
• Autosomal recessive inheritance – both parents must carry a defective copy. Carriers are usually asymptomatic.

Acquired Causes

• Liver disease – cirrhosis, hepatitis, or fatty liver reduces synthesis of fibrinogen.
• Disseminated intravascular coagulation (DIC) – consumes fibrinogen rapidly.
• Massive transfusion or massive hemorrhage – dilutional coagulopathy.
• Severe sepsis or inflammation – cytokine storm may impair production.
• Medications – some anticoagulants (e.g., direct thrombin inhibitors) and certain antiplatelet agents can lower fibrinogen levels.
• Pregnancy – fibrinogen normally rises; however, women with borderline hypofibrinogenemia may develop clinically significant deficiency during the third trimester.

Risk Factors

• Family history of bleeding disorders.
• Consanguineous parentage.
• Chronic liver disease, especially alcoholic or viral cirrhosis.
• Conditions associated with DIC (e.g., severe trauma, obstetric complications).
• Use of drugs that interfere with hepatic protein synthesis.

Diagnosis

Because fibrinogen deficiency mimics many other bleeding disorders, a systematic work‑up is essential.

Laboratory evaluation

• Plasma fibrinogen level – measured by Clauss assay (functional) or immunologic assay. Normal range: 200–400 mg/dL. Levels <10 mg/dL indicate afibrinogenemia; 10–150 mg/dL suggest hypofibrinogenemia.
• Prothrombin time (PT) and activated partial thromboplastin time (aPTT) – both are typically prolonged in severe deficiency because fibrinogen is a substrate for thrombin.
• Thrombin clot‑formation test – assesses the ability of plasma to generate a stable clot.
• Platelet count and function tests – to rule out concurrent thrombocytopenia.
• Liver function tests (ALT, AST, bilirubin, albumin) – useful in suspected acquired cases.

Genetic testing

For suspected congenital disease, sequencing of the three fibrinogen genes (FGA, FGB, FGG) confirms the diagnosis. Carrier testing is offered to siblings and future parents.

Imaging (when indicated)

• CT or MRI of the head for unexplained neurological symptoms (to detect intracranial hemorrhage).
• Ultrasound of the abdomen in patients with liver disease.

Diagnostic criteria summary

Finding	Afibrinogenemia	Hypofibrinogenemia	Acquired
Fibrinogen level	<10 mg/dL	10–150 mg/dL	Variable, often <150 mg/dL
PT / aPTT	Markedly prolonged	Prolonged	Prolonged if severe
Genetic mutation	Present	Sometimes	Absent

Treatment Options

Treatment goals are to prevent bleeding, manage acute hemorrhage, and address any underlying acquired condition.

Acute Bleeding Management

• Fibrinogen concentrate (e.g., Fibryga, RiaSTAP) – the preferred first‑line therapy for both congenital and acquired deficiency. Typical dosing: 3–4 g (≈ 50–70 mg/kg) to raise levels above 100 mg/dL.
• Fresh frozen plasma (FFP) – contains ~2–3 g/L fibrinogen; used when concentrate is unavailable. Requires large volumes (10–15 mL/kg), which may precipitate volume overload.
• Cryoprecipitate – concentrated fibrinogen (~15–20 mg/mL) but carries higher infection risk; dosing ≈ 1 unit per 5 kg body weight.
• Tranexamic acid – antifibrinolytic that stabilizes clots; 10 mg/kg IV over 10 min then 1 mg/kg/hr. Useful adjunct, especially in mucosal bleeding.

Prophylactic Treatment

• Regular prophylactic fibrinogen concentrate infusions (e.g., every 1–2 weeks) in patients with frequent bleeding or undergoing surgery.
• Pregnant women with known deficiency often receive prophylaxis during the third trimester and peripartum period to maintain fibrinogen >150 mg/dL.

Management of Acquired Causes

• Liver disease – treat underlying hepatitis, abstain from alcohol, consider liver transplantation in end‑stage disease.
• DIC – treat the trigger (infection, trauma) and give supportive fibrinogen replacement.
• Medication review – discontinue or adjust drugs that impair fibrinogen synthesis.

Other Therapeutic Considerations

• Vaccination against hepatitis B to protect liver function.
• Genetic counseling for families with congenital forms.
• Dental prophylaxis and coordination with oral surgeons to plan local hemostatic measures.

Living with Fibrinogen Deficiency

While the condition is chronic, most individuals can lead active lives with proper planning.

Daily Management Tips

• Carry a medical alert card indicating “Fibrinogen deficiency – requires replacement if bleeding.
• Maintain a personal bleeding diary (date, location, severity) to help clinicians adjust prophylaxis.
• Use soft toothbrushes and avoid flossing aggressively to limit gum bleeding.
• Apply pressure promptly to cuts and keep a small first‑aid kit with tranexamic acid tablets.
• Avoid NSAIDs (ibuprofen, aspirin) unless specifically approved, as they impair platelet function.
• Schedule regular follow‑up labs (fibrinogen level, liver enzymes) every 3–6 months.
• Women should discuss menstrual management with a gynecologist; hormonal therapy or IUDs can reduce menorrhagia.
• Plan ahead for surgeries—inform surgeons well in advance so that replacement therapy can be scheduled.

Psychosocial Support

Joining patient support groups (e.g., Rare Bleeding Disorders Association) can provide emotional support and practical advice. Mental health screening is recommended, as chronic bleeding disorders are associated with anxiety and depression.<sup>[4]</sup>

Prevention

Because the inherited form cannot be “prevented,” the focus is on minimizing bleeding triggers and managing modifiable risks.

• Control liver disease – avoid alcohol, receive antiviral therapy for hepatitis, maintain a healthy weight.
• Vaccinations – hepatitis A & B, influenza, and COVID‑19 reduce infection‑related liver injury.
• Safe medication use – discuss all over‑the‑counter drugs with your hematologist.
• Injury prevention – use protective gear for sports, avoid high‑impact activities if you have a history of joint bleeds.
• Pregnancy planning – pre‑conception counseling and early obstetric care help maintain adequate fibrinogen levels throughout gestation.

Complications

If untreated or inadequately managed, fibrinogen deficiency can lead to serious health issues.

Bleeding‑related complications

• Life‑threatening intracranial or intra‑abdominal hemorrhage.
• Chronic anemia from recurrent gastrointestinal or menstrual bleeding.
• Joint damage (arthropathy) due to repeated hemarthrosis.
• Post‑operative hematoma formation, which may require re‑exploration.

Complications from treatment

• Allergic reactions or anaphylaxis to fibrinogen concentrates (rare).
• Thrombotic events if fibrinogen levels are overshot (>400 mg/dL) especially in patients with other risk factors (e.g., smoking, sedentary lifestyle).
• Volume overload from repeated FFP transfusions.

When to Seek Emergency Care

References

• 1. Peyvandi F, et al. “Inherited fibrinogen disorders.” Blood. 2020;136(22):2506‑2517.
• 2. Girolami A, et al. “Epidemiology of congenital fibrinogen deficiencies.” Haemophilia. 2021;27(5):834‑842.
• 3. WHO. “Global hepatitis report 2022.” World Health Organization.
• 4. Scharrer I, et al. “Psychosocial burden of rare bleeding disorders.” J Thromb Haemost. 2022;20(4):785‑793.
• 5. Mayo Clinic. “Fibrinogen deficiency.” Accessed May 2026. https://www.mayoclinic.org/…
• 6. CDC. “Liver disease and bleeding disorders.” Updated 2024. https://www.cdc.gov/hepatitis

```